<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03025542</url>
  </required_header>
  <id_info>
    <org_study_id>PS0016</org_study_id>
    <secondary_id>2016-002368-15</secondary_id>
    <nct_id>NCT03025542</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis</brief_title>
  <official_title>A Multicenter, Randomized, Subject-Blind, Investigator-Blind Study to Evaluate the Time Course of Pharmacodynamic Response, Safety and Pharmacokinetics of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2a, multicenter, randomized, subject-blind, investigator-blind, study to
      investigate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of bimekizumab in
      adult subjects with moderate to severe chronic plaque psoriasis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Psoriasis Area and Severity Index (PASI) at Week 28</measure>
    <time_frame>Week 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean plasma concentration of bimekizumab at Week 16</measure>
    <time_frame>Week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants reporting positive Anti-Drug-Antibodies (ADA) titre prior to and following study treatment with bimekizumab</measure>
    <time_frame>From Baseline to the End of Treatment (Week 28)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>From Baseline to Safety Follow Up Visit (Week 36)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects achieving a 75% or higher improvement from Baseline in PASI (Psoriasis Area and Severity Index) score at Week 16</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects achieving a 90% or higher improvement in PASI (Psoriasis Area and Severity Index) score at Week 16</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects achieving a 100% improvement from Baseline in PASI (Psoriasis Area and Severity Index) score at Week 16</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with IGA (InvestigatorÂ´s Global Assessment) response at Week 16</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Chronic Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized in this arm will receive a combination of Bimekizumab and Placebo injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized in this arm will receive Bimekizumab injections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bimekizumab</intervention_name>
    <description>Based on their randomization subjects will receive a combination of several injections of Bimekizumab.</description>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <other_name>UCB4940</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive injections of Placebo.</description>
    <arm_group_label>Treatment Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female at least 18 years of age and less than or equal to 70

          -  Chronic plaque psoriasis for at least 6 months prior to Screening

          -  Psoriasis Area and Severity Index (PASI) &gt;=12 and body surface area (BSA) &gt;=10% and
             Investigator's Global Assessment (IGA) score &gt;=3 on a 5-point scale

          -  Candidates for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy

          -  Female subjects must be postmenopausal, permanently sterilized or, if of childbearing
             potential, must be willing to use a highly effective method of contraception up till
             20 weeks after last administration of study drug, and have a negative pregnancy test
             at Visit 1 (Screening) and immediately prior to first dose

          -  Male subjects with a partner of childbearing potential must be willing to use a condom
             when sexually active, up till 20 weeks after the last administration of study
             medication (anticipated 5 half-lives)

        Exclusion Criteria:

          -  Subjects previously participating in a bimekizumab study

          -  Subjects with erythrodermic, guttate, pustular form of psoriasis, or drug-induced
             psoriasis

          -  History of chronic or recurrent infections, or a serious or life-threatening infection
             within the 6 months prior to the Baseline Visit (including herpes zoster)

          -  High risk of infection in the Investigator's opinion

          -  Current sign or symptom that may indicate an active infection

          -  Concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus
             (HIV) infection

          -  Live (includes attenuated) vaccination within the 8 weeks prior to Baseline

          -  Subjects with concurrent malignancy or history of malignancy during the past 5 years
             (except for specific malignant condition as defined in the protocol)

          -  Primary immunosuppressive conditions

          -  TB infection, high risk of acquiring TB infection, latent TB infection (LTBI), or
             current or history of NTMB infection

          -  Laboratory abnormalities, as defined in the study protocol

          -  Any condition which, in the Investigator's judgement, would make the subject
             unsuitable for inclusion in the study

          -  Exposure to more than 1 biological response modifier (limited to anti-TNF or
             IL-12/-23) or any biologic response modifier during the three months prior to the
             Baseline Visit

          -  Subjects have received previous treatment with any anti-IL-17 therapy for the
             treatment of psoriasis or psoriatic arthritis

          -  Subjects with a diagnosis of inflammatory conditions other than psoriasis or psoriatic
             arthritis, including but not limited to rheumatoid arthritis, sarcoidosis, or systemic
             lupus erythematosus. Subjects with a diagnosis of Crohn's disease or ulcerative
             colitis are allowed as long as they have no active symptomatic disease at Screening or
             Baseline

          -  Subjects taking psoriatic arthritis medications other than nonsteroidal
             anti-inflammatory drugs (NSAIDs) or analgesics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>+1 844 599 2273(UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ps0016 704</name>
      <address>
        <city>Bexley</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0016 102</name>
      <address>
        <city>Kogarah</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0016 101</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0016 104</name>
      <address>
        <city>Woolloongabba</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0016 201</name>
      <address>
        <city>Ajax</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0016 203</name>
      <address>
        <city>London</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0016 202</name>
      <address>
        <city>Windsor</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0016 501</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Moldova, Republic of</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2017</study_first_submitted>
  <study_first_submitted_qc>January 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2017</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Chronic Plaque Psoriasis</keyword>
  <keyword>Bimekizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

